Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04648969 · ClinicalTrials.gov registry record · Phase 2
Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism
A Phase 2 study, sponsored by Stephanie B. Seminara, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT04648969 is a Phase 2 study that has completed, run by Stephanie B. Seminara, MD. The registered enrollment target is 18 participants.
The verdict
NCT04648969, a Phase 2 study, has completed, sponsored by Stephanie B. Seminara, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The goal of this study is to develop novel treatments for patients with a condition called hypogonadotropic hypogonadism (HH) through the use of exogenous kisspeptin.
Interventions
- DRUG kisspeptin 112-121
- DRUG GnRH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-05-03 |
| Est. Completion | 2025-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04648969
The ClinicalTrials.gov registry entry for NCT04648969 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stephanie B. Seminara, MD, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which kisspeptin 112-121 is the first listed.
NCT04648969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04648969 about?
NCT04648969 is a clinical study titled "Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism". The goal of this study is to develop novel treatments for patients with a condition called hypogonadotropic hypogonadism (HH) through the use of exogenous kisspeptin.
What is the current status of trial NCT04648969?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2019-05-03. Estimated completion is 2025-08-31.
What interventions are being tested in trial NCT04648969?
The interventions under investigation include: kisspeptin 112-121 (DRUG), GnRH (DRUG).
Who is sponsoring clinical trial NCT04648969?
This trial is sponsored by Stephanie B. Seminara, MD, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.